2,4-di(propan-2-yl)-2H-imidazole

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,4-di(propan-2-yl)-2H-imidazole
• 化学式: C₉H₁₆N₂
• 分子量: 152.24
• InChiKey: FKLBATFOOUMXJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。
• Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10975055B2

  公开（公告）日：2021-04-13

  The present invention provides novel compounds of Formula (I′), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.

  本发明提供了式(I′)的新型化合物及其药学上可接受的盐、溶液剂、水合物、多晶体、共晶体、同系物、立体异构体、同位素标记的衍生物、原药及其组合物。还提供了涉及本发明化合物或组合物的方法和试剂盒，用于治疗和/或预防受试者的增殖性疾病（如癌症（如白血病、淋巴瘤））、炎症性疾病、自身炎症性疾病和自身免疫性疾病。使用本发明的化合物或组合物治疗患有增殖性疾病的受试者，可抑制受试者体内激酶的异常活性，如白细胞介素-1受体相关激酶（IRAK）（如IRAKI和/或IRAK4）。
• INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20190276426A1

  公开（公告）日：2019-09-12

  The present invention provides novel compounds of Formula (I′), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.
• US9422267B2
  申请人：——

  公开号：US9422267B2

  公开（公告）日：2016-08-23